Zamami Yoshito, Niimura Takahiro, Koyama Toshihiro, Shigemi Yuta, Izawa-Ishizawa Yuki, Morita Mizuki, Ohshima Ayako, Harada Keisaku, Imai Toru, Hagiwara Hiromi, Okada Naoto, Goda Mitsuhiro, Takechi Kenshi, Chuma Masayuki, Kondo Yutaka, Tsuchiya Koichiro, Hinotsu Shiro, Kano Mitsunobu R, Ishizawa Keisuke
Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
Front Pharmacol. 2019 Nov 8;10:1257. doi: 10.3389/fphar.2019.01257. eCollection 2019.
The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using "TargetMine," a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the "survival discharge." Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients.
心脏骤停患者的存活率低于10%;因此,有必要制定一种改善其预后的治疗策略。在此,我们在日本各地医疗机构收集的数据中搜索可提高心脏骤停患者存活率的药物。利用药物发现工具“TargetMine”提取了可能改善心脏骤停患者预后的候选药物。我们在从日本医疗数据中心获得的心脏骤停病例数据中,调查了这些候选药物是否在心脏骤停后1个月内给药。进行了逻辑回归分析,解释变量为给予≥10例患者的那些候选药物的给药情况,目标变量为“存活出院”。对于显著提高存活出院比例的药物,使用倾向评分计算存活出院的调整优势比;通过治疗逆概率加权法排除了患者背景、病史和治疗因素等协变量的影响。使用该搜索策略,我们提取了165种具有血管舒张活性的药物作为候选药物。排除了在日本未获批的药物、口服药物和外用药物。然后,我们调查了这些候选药物是否给予了本研究纳入的2227例心脏骤停患者。逻辑回归分析结果显示,给予≥10例患者的7种药物中有3种(硝酸异山梨酯、硝酸甘油和尼卡地平)与存活出院比例的改善显著相关。使用倾向评分的进一步分析显示,给予硝酸异山梨酯、硝酸甘油和尼卡地平的患者存活出院的调整优势比分别为3.35、5.44和4.58。因此,可以认为硝酸异山梨酯、硝酸甘油和尼卡地平可能是改善心脏骤停患者预后的新型治疗药物。